FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091358512> ?p ?o ?g. }

• W2091358512 endingPage "711" @default.
• W2091358512 startingPage "704" @default.
• W2091358512 abstract "Selegiline (L-deprenyl) is a selective irreversible monoamine oxidase B inhibitor shown to be effective in the treatment of Parkinson's and Alzheimer's diseases. Recent evidence suggests that selegiline may also be useful in treating specific aspects of cocaine and nicotine dependence, generating interest in this compound for the treatment of methamphetamine addiction. To investigate this, we performed a randomized, single-blind, placebo-controlled study to evaluate the safety of selegiline treatment (as compared to placebo), concurrent with intravenous methamphetamine (15 or 30 mg). Secondary study objectives included determinations of plasma levels of selegiline and its metabolites, evaluating whether selegiline administration altered the pharmacokinetics of methamphetamine or its metabolites, and evaluating whether selegiline treatment alters the subjective responses to methamphetamine. Twenty-four methamphetamine-dependent participants were randomized to treatment, and 9 of these (N = 5 selegiline, N = 4 placebo) completed the entire protocol. The principal finding from this study was that intravenous administration of moderate doses of methamphetamine was safely tolerated during treatment with selegiline. No participants had electrocardiogram changes, and there were no meaningful differences in any laboratory values either between groups at screening or as a result of the study procedures. In general, adverse events were mild or moderate, and no subjects were discontinued due to adverse events or serious adverse events. Selegiline treatment did not enhance any of the cardiovascular changes (heart rate, blood pressure) produced by methamphetamine administration. Selegiline treatment slightly increased methamphetamine associated bad effects but did not alter any other subjective effects. The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine. The available data suggest that selegiline is likely to be safe if used as a pharmacotherapy for methamphetamine dependence." @default.
• W2091358512 created "2016-06-24" @default.
• W2091358512 creator A5007825628 @default.
• W2091358512 creator A5009663763 @default.
• W2091358512 creator A5016497110 @default.
• W2091358512 creator A5030381992 @default.
• W2091358512 creator A5056109933 @default.
• W2091358512 creator A5064463152 @default.
• W2091358512 creator A5066830595 @default.
• W2091358512 creator A5071534147 @default.
• W2091358512 date "2005-12-01" @default.
• W2091358512 modified "2023-09-25" @default.
• W2091358512 title "A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline" @default.
• W2091358512 cites W1819674547 @default.
• W2091358512 cites W1974655113 @default.
• W2091358512 cites W1989554708 @default.
• W2091358512 cites W1997174539 @default.
• W2091358512 cites W2001940545 @default.
• W2091358512 cites W2009240733 @default.
• W2091358512 cites W2021534324 @default.
• W2091358512 cites W2023590101 @default.
• W2091358512 cites W2024501939 @default.
• W2091358512 cites W2031243365 @default.
• W2091358512 cites W2039853499 @default.
• W2091358512 cites W2040276248 @default.
• W2091358512 cites W2057069444 @default.
• W2091358512 cites W2069162251 @default.
• W2091358512 cites W2072187292 @default.
• W2091358512 cites W2126683634 @default.
• W2091358512 cites W2141204033 @default.
• W2091358512 cites W2144176813 @default.
• W2091358512 cites W2165398609 @default.
• W2091358512 cites W2338649220 @default.
• W2091358512 cites W89851913 @default.
• W2091358512 cites W1982297364 @default.
• W2091358512 doi "https://doi.org/10.1016/j.pbb.2005.11.012" @default.
• W2091358512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16413604" @default.
• W2091358512 hasPublicationYear "2005" @default.
• W2091358512 type Work @default.
• W2091358512 sameAs 2091358512 @default.
• W2091358512 citedByCount "20" @default.
• W2091358512 countsByYear W20913585122012 @default.
• W2091358512 countsByYear W20913585122017 @default.
• W2091358512 countsByYear W20913585122018 @default.
• W2091358512 countsByYear W20913585122020 @default.
• W2091358512 countsByYear W20913585122021 @default.
• W2091358512 crossrefType "journal-article" @default.
• W2091358512 hasAuthorship W2091358512A5007825628 @default.
• W2091358512 hasAuthorship W2091358512A5009663763 @default.
• W2091358512 hasAuthorship W2091358512A5016497110 @default.
• W2091358512 hasAuthorship W2091358512A5030381992 @default.
• W2091358512 hasAuthorship W2091358512A5056109933 @default.
• W2091358512 hasAuthorship W2091358512A5064463152 @default.
• W2091358512 hasAuthorship W2091358512A5066830595 @default.
• W2091358512 hasAuthorship W2091358512A5071534147 @default.
• W2091358512 hasConcept C126322002 @default.
• W2091358512 hasConcept C142724271 @default.
• W2091358512 hasConcept C168563851 @default.
• W2091358512 hasConcept C197934379 @default.
• W2091358512 hasConcept C204787440 @default.
• W2091358512 hasConcept C27081682 @default.
• W2091358512 hasConcept C2776134090 @default.
• W2091358512 hasConcept C2779134260 @default.
• W2091358512 hasConcept C2779734285 @default.
• W2091358512 hasConcept C2780376393 @default.
• W2091358512 hasConcept C42219234 @default.
• W2091358512 hasConcept C71924100 @default.
• W2091358512 hasConcept C98274493 @default.
• W2091358512 hasConceptScore W2091358512C126322002 @default.
• W2091358512 hasConceptScore W2091358512C142724271 @default.
• W2091358512 hasConceptScore W2091358512C168563851 @default.
• W2091358512 hasConceptScore W2091358512C197934379 @default.
• W2091358512 hasConceptScore W2091358512C204787440 @default.
• W2091358512 hasConceptScore W2091358512C27081682 @default.
• W2091358512 hasConceptScore W2091358512C2776134090 @default.
• W2091358512 hasConceptScore W2091358512C2779134260 @default.
• W2091358512 hasConceptScore W2091358512C2779734285 @default.
• W2091358512 hasConceptScore W2091358512C2780376393 @default.
• W2091358512 hasConceptScore W2091358512C42219234 @default.
• W2091358512 hasConceptScore W2091358512C71924100 @default.
• W2091358512 hasConceptScore W2091358512C98274493 @default.
• W2091358512 hasIssue "4" @default.
• W2091358512 hasLocation W20913585121 @default.
• W2091358512 hasLocation W20913585122 @default.
• W2091358512 hasOpenAccess W2091358512 @default.
• W2091358512 hasPrimaryLocation W20913585121 @default.
• W2091358512 hasRelatedWork W125244611 @default.
• W2091358512 hasRelatedWork W1540734923 @default.
• W2091358512 hasRelatedWork W177866514 @default.
• W2091358512 hasRelatedWork W1998621094 @default.
• W2091358512 hasRelatedWork W2020644391 @default.
• W2091358512 hasRelatedWork W2041878706 @default.
• W2091358512 hasRelatedWork W2045356184 @default.
• W2091358512 hasRelatedWork W2066525586 @default.
• W2091358512 hasRelatedWork W2127860867 @default.
• W2091358512 hasRelatedWork W2148177282 @default.
• W2091358512 hasVolume "82" @default.
• W2091358512 isParatext "false" @default.

• next